Gastrointestinal SLE involvement in SLE classification. Response to: “2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al’ by Cui et al

Dear Sir,

In their letter, Dr Cui and colleagues include two interesting thoughts. Primarily, they argue, illustrated by one case, that gastrointestinal (GI) involvement may be more common in systemic lupus erythematosus (SLE) than usually thought. This thought is to some degree supported by the patient survey performed within the European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) classification criteria project, in which we noted that more than 50% of the patients reported GI symptoms at the time of their SLE diagnosis, even though this organ system was not included on the questionnaire.

However, no specific SLE GI pattern has been described so far, which would be a prerequisite of including a GI manifestation into SLE classification criteria. A large number of rare organ manifestations possible in SLE could not be included into the classification criteria, since this would be impracticable. Throughout the classification criteria development process, SLE experts opined for a comprehensive system balanced against computational ease in the clinic. As in most instances, SLE affected multiple organs in the authors’ patient, easily allowing for classification according to the EULAR/ACR 2019 SLE classification criteria. On the other hand, in unusual situations of rare, isolated organ manifestations, failure to fulfill classification criteria should never prevent making a clinical diagnosis. While both try to correctly define whether a patient has SLE or not, diagnosis and classification are clearly distinct, and we once again caution against using the EULAR/ACR 2019 classification criteria for making or even worse refuting a diagnosis of SLE. As result of a very stringent methodological process, lack of sufficient homogeneity of GI manifestations did not qualify as a classification domain, but this does not argue against their clinical occurrence.

The other idea Dr Cui et al express is direct translation of points received in the EULAR/ACR classification system to the probability that the patient has SLE. This has not yet been tried, but the line of thought is correct in that the system in fact provides for a measure of the probability a patient can be classified as having SLE.

Martin Aringer 1, Karen H Costenbader 2, Thomas Dörner 3,4, Sindhu R Johnson 5,6

1Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany
2Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
3Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
4Department of Rheumatology and Clinical Immunology, Berlin Institute of Health, Berlin, Berlin, Germany
5Division of Rheumatology, Department of Medicine, Toronto Western Hospital, University Health Network, Mount Sinai Hospital, University of Toronto, Toronto Scleroderma Research Program, Toronto, Ontario, Canada
6University of Toronto Institute of Health Policy Management and Evaluation, Toronto, Ontario, Canada

Correspondence to Professor Martin Aringer, Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany; martin.aringer@uniklinikum-dresden.de

Handling editor Josef S Smolen

Contributors All authors have drafted the response together and agree with the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial reuse. See rights and permissions. Published by BMJ.

To cite Aringer M, Costenbader KH, Dörner T, et al, Ann Rheum Dis Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-218615

Received 20 July 2020
Accepted 21 July 2020

► http://dx.doi.org/10.1136/annrheumdis-2020-218546

Ann Rheum Dis 2020:0. doi:10.1136/annrheumdis-2020-218615

ORCID iDs
Martin Aringer http://orcid.org/0000-0003-4471-8375
Thomas Dörner http://orcid.org/0000-0002-6478-7725
Sindhu R Johnson http://orcid.org/0000-0003-0591-2976

REFERENCES